Literature DB >> 21503629

Can intravenous colistin effectively treat ventilator-associated pneumonia in the pediatric and neonatal patients?

Narongsak Nakwan, Kulkanya Chokephaibulkit.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21503629     DOI： 10.1007/s00431-011-1478-6

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  5 in total

1.  Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report.

Authors:  Narongsak Nakwan; Jeerawan Wannaro; Tipaporn Thongmak; Pornpat Pornladnum; Ratchanee Saksawad; Narongwit Nakwan; Kulkanya Chokephaibulkit
Journal:  Pediatr Pulmonol       Date:  2010-09-01

2.  Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa.

Authors:  Qin Lu; Cassio Girardi; Mao Zhang; Belaïd Bouhemad; Kamel Louchahi; Olivier Petitjean; Frédéric Wallet; Marie-Helene Becquemin; Gilles Le Naour; Charles-Hugo Marquette; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2010-04-16       Impact factor: 17.440

3.  Colistin administration to pediatric and neonatal patients.

Authors:  Elias Iosifidis; Charalampos Antachopoulos; Maria Ioannidou; Magda Mitroudi; Maria Sdougka; Vassiliki Drossou-Agakidou; Maria Tsivitanidou; Emmanuel Roilides
Journal:  Eur J Pediatr       Date:  2010-01-30       Impact factor: 3.183

4.  Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.

Authors:  Roberto Imberti; Maria Cusato; Paola Villani; Livio Carnevale; Giorgio A Iotti; Martin Langer; Mario Regazzi
Journal:  Chest       Date:  2010-06-17       Impact factor: 9.410

5.  The pharmacokinetics and tissue levels of polymyxin B, colistin and gentamicin in calves.

Authors:  G Ziv; J F Nouws; C A van Ginneken
Journal:  J Vet Pharmacol Ther       Date:  1982-03       Impact factor: 1.786
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.